Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 183 clinical trials
None
AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia

with ATRA and idarubicin followed by postremission therapy with daunorubicin and mitoxantrone in age adapted dosages. Patients with an high WBC were additionally treated with cytarabine

idarubicin
retinoids
induction therapy
tretinoin
mitoxantrone
  • 40 views
  • 07 Nov, 2020
  • 1 location
None
Efficacy of G-CSF-Priming in Elderly AML Patients

Aim of the study is to compare the efficacy of intensive induction therapy with Cytarabine, Idarubicin and Etoposide (IdAV) given in parallel with (G-CSF priming) and followed by G-CSF

idarubicin
granulocyte colony stimulating factor
cytarabine
cell transplantation
neoadjuvant therapy
  • 50 views
  • 07 Nov, 2020
  • 1 location
None
Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia

treatment of relapsed/refractory acute myeloid leukemia in adult patients (intensive chemotherapy amsacrine-cytarabine or azacitidine according to investigator's willingness) results in a significant

  • 0 views
  • 25 Jan, 2021
  • 5 locations
None
Study of Magrolimab Combinations in Participants With Myeloid Malignancies

therapies of venetoclax (Ven) and azacitidine (Aza) (Cohort 1), mitoxantrone, etoposide, and cytarabine (MEC) (Cohort 2) and CC-486 (Cohort 3) respectively in participants with acute myeloid leukemia (AML

  • 0 views
  • 29 Nov, 2021
  • 6 locations
None
High-Dose Sequential Chemoimmunotherapy for B-Cell Lymphomas With Central Nervous System Involvement

This prospective trial will assess the activity and feasibility of a new high-dose methotrexate-based high-dose sequential chemotherapy combination in patients with B-cell lymphomas and CNS involvement at diagnosis or relapse. Selected drugs, with a well-documented anti-lymphoma activity, will be administered at high doses to increase blood-brain barrier penetration and CNS …

chemoimmunotherapy
cancer
methotrexate
  • 4 views
  • 07 Nov, 2020
  • 1 location
None
Venetoclax SL-401 and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

This phase II trial studies how well venetoclax, SL-401, and chemotherapy works in treating patients with blastic plasmacytoid dendritic cell neoplasm. Venetoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. SL-401 is a recombinant protein consisting of IL-3 linked to a …

  • 0 views
  • 30 Jan, 2021
None
Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML

intermediate dose of cytarabine. In the control arm, patients receive DA regimen with standard dose of cytarabine.The efficacy of induction therapy containing intermediate dose of cytarabine is evaluated and

daunorubicin
cytarabine/daunorubicin
neoadjuvant therapy
adult acute myelogenous leukemia
cytarabine
  • 36 views
  • 23 Jan, 2021
  • 1 location
None
Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML)

The purpose of this study is to compare the clinical efficacy and safety of IAC regimen and IA regimen as induction chemotherapy for initial diagnosed AML patients. 840 cases are supposed to recruited in 3 years.

idarubicin
cladribine
induction chemotherapy
ara-c
cytarabine
  • 26 views
  • 24 Jan, 2021
  • 1 location
None
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia

with cytarabine plus mitoxantrone or liposomal daunorubicin in induction To compare mitoxantrone (anthracenedione) & cytarabine with liposomal daunorubicin (anthracycline) &amp

idarubicin
daunorubicin
residual tumor
flow cytometry
induction chemotherapy
  • 0 views
  • 17 Oct, 2021
  • 61 locations
None
Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 (olutasidenib) as a single agent or in combination with azacitidine or cytarabine. The Phase 1 stage of the study

azacitidine
leukemia
aml/mds
myeloid leukemia
acute promyelocytic leukemia
  • 0 views
  • 22 Aug, 2021
  • 95 locations